Seoul Bio Hub announced that it will hold the '2025 Seoul Bio-Medical Open Collaboration (hereinafter referred to as Open Collaboration)' on November 26th.
This event, themed "Biotechnology Growth Chain," will officially showcase the newly launched "Open Innovation Chain." This "Open Innovation Chain" is a growth chain model where biotech startups' technologies develop through collaborations with large and medium-sized companies, followed by joint research and technology transfer with global pharmaceutical companies (Big Pharma). By incorporating venture capital (VC) participation, the event establishes a structure that simultaneously promotes the commercialization of innovative technologies and attracts investment.
Open Collaboration consists of two sessions, one in the morning and one in the afternoon. In the first session, major domestic pharmaceutical and biotech companies will share their open innovation strategies. Key presenters include ▲ SK Biopharmaceuticals Vice President Hwang Seon-gwan (New Drug Development Strategy for Intractable Brain Diseases), ▲ ABL Bio Director Jeong Jin-won (Partnership in the Era of New Modalities), ▲ Huons Director Eum Hyeon-ae (Open Innovation Strategy and Case Studies), ▲ HK inno.N Managing Director Kim Bong-tae (Open Innovation Promotion Direction), and ▲ HLB Managing Director Nam Gyeong-sook (HLB Bio Eco-System and Shared Growth Strategy).
In the second half of the afternoon, 1:1 partnerships will take place between 33 startups matched through the "Bio Open Innovation Chain" and large and medium-sized enterprises. Additionally, eight startups recommended by investors will take the stage to present their IR pitches.
Seoul Bio Hub launched an open innovation chain in partnership with the Korea Innovative Medicines Consortium (KIMCo) in June and has since established a collaborative network with large and medium-sized companies and biotech venture capital firms. Participating companies include Dong-A ST, Liga Chem Bio, ABL Bio, Olix, Genome & Company, T&L, and Huons. Investors include CKD Venture Capital, LSK Investment, Daekyo Investment, Scaleup Partners, Solidus Investment, Shinhan Venture Investment, and Aju IB Investment.
A Seoul Bio Hub official stated, “This event will be the first to concretize the open innovation system in the bio industry, and will serve as a venue for cooperation where startup technology, industry, and investment are organically linked.”
- See more related articles
You must be logged in to post a comment.